Epidemiological Transition and Forecasting of Diabetes Burden in Saudi Arabia: A Comprehensive Analysis From the Global Burden of Disease Study 1990–2023

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

Sugary beverages increase the risk of pattern hair loss in men by 57%, and type 2 diabetes is linked to female pattern hair loss. Reducing sugar intake and using treatments like finasteride and minoxidil may help manage hair loss.

Long-term use of finasteride and dutasteride may be linked to health risks like fatty liver disease, insulin resistance, type 2 diabetes, dry eye disease, and potential kidney disease. Some users believe the risks are low and the medications are generally safe.

A 22-year-old male with high estrogen levels is considering finasteride for hair loss but is concerned about potential side effects due to his hormone levels and family history of diabetes. Users suggest consulting a doctor, possibly an endocrinologist, and considering lifestyle changes like diet and exercise to address visceral fat and insulin resistance before starting treatment.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.